Background
==========

Cartilage provides a scaffold for the deposition of osteoblast precursors and ultimately the development of long bones. This process, termed endochondral ossification, describes a coordinated developmental series that involves commitment of mesenchymal precursor cells to the chondrogenic lineage and subsequent alternating phases of proliferation and differentiation, which culminate in the replacement of the cartilage by bone tissue \[[@B1]-[@B4]\]. In the first phase of this process, multipotent mesenchymal progenitors condense and initiate expression of the pro-chondrogenic Sox family members 9, 5 and 6 \[[@B5],[@B6]\]. A subset of cells at the center of these aggregates differentiates into chondrocytes. Newly formed chondrocytes secrete an extracellular matrix rich in type II collagen (*Col2a1*), proliferate and ultimately terminally differentiate into hypertrophic chondrocytes \[[@B7]\]. Chondrocyte hypertrophy precedes the end of the chondrocyte life cycle by apoptosis and is accompanied by vascularization of the hypertrophic template and mineralization of the cartilaginous extracellular matrix \[[@B8]-[@B12]\]. Concomitantly, osteoclasts degrade the calcified cartilage extracellular matrix, making way for the invasion and deposition of an osteoprogenitor population that form the primary ossification center \[[@B13]\].

These events take place in a region called the growth plate that illustrates the organization of different phases of cartilage development into distinct zones. The resting zone delineates newly differentiated chondrocytes with low mitotic activity and the cellular reserve for subsequent stages of chondrocyte differentiation. Proliferative zone chondrocytes exhibit higher mitotic activity resulting in distinct columns containing cells reminiscent of stacked coins. The hypertrophic zone demarcates terminally differentiated chondrocytes which are identified by high cytoplasm to nuclear ratio and the expression of type X collagen (Col10a1) \[[@B14]-[@B16]\]. Terminally differentiated chondrocytes are fated for programmed cell death after which primary ossification occurs by way of vascularization of the remaining cartilaginous matrix and the deposition of osteoprogenitor cells \[[@B17]-[@B19]\].

Glucocorticoids (GC) are among various endocrine molecules including growth hormone (GH) and thyroid hormone (TH) known to regulate linear growth \[[@B20]-[@B23]\]. Regulation of linear growth follows the paradigm in which steroid hormones affect target tissue through both local and systemic mechanisms \[[@B24]-[@B27]\]. Indirect effects occur through modulation of other endocrine systems such as the GH/IGF-I axis. Generally, GC decrease IGF-I, GH receptor and IGF receptor 1 expression and also abrogate the release of GH from the pituitary \[[@B20],[@B28],[@B29]\]. Direct regulation of growth occurs through GC receptor (GR)-mediated gene transcription in chondrocytes \[[@B24],[@B30],[@B31]\].

GC functions are primarily mediated by the glucocorticoid receptor (GR) that is encoded by the *Nr3c1*gene. The GR is ubiquitously expressed in mammalian tissues, including the growth plate, and is essential for life \[[@B31]-[@B36]\]. Many studies have examined GC regulation of the skeleton and have led to various theories on potential modes of GC function in cartilage \[[@B37]-[@B40]\]. The specific function of the receptor in terms of its transcriptional regulation in cartilage, however, remains enigmatic.

While endogenous GCs have been shown to promote the differentiation of both chondrocytes and osteoblasts, exogenous GCs in pharmacological doses which are also widely used in clinical practice to treat inflammatory disorders \[[@B41]-[@B46]\]. Their have different effects. Indeed, their utility in treating various diseases is, however, limited by numerous side effects such as growth failure and decreased bone quality \[[@B47]\]. GC-target genes including C-type natriuretic peptide and VEGF have been identified in chondrocytes \[[@B28],[@B48],[@B49]\]; however, the cartilage-specific transcriptional consequences of high-GC-doses in the growth plate have not been studied comprehensively.

Work in our laboratory identified GR amongst factors that were up-regulated during chondrocyte maturation \[[@B50]\] Thus, to comprehensively understand the transcriptional effects of pharmacological GC doses in growth plate, we completed a genomic screen of gene expression changes in chondrocytes derived from E15.5 day old mouse embryos. Primary monolayer chondrocytes were treated with a synthetic GC, dexamethasone (DEX), and RNA was isolated for microarray analysis. We complemented traditional microarray analysis methods with the gene set enrichment algorithm to correlate the behaviour of specific molecular classes with DEX treatment \[[@B51],[@B52]\].

Results and Discussion
======================

Microarray screen of dexamethasone-treated primary chondrocyte monolayers
-------------------------------------------------------------------------

We identified the GR as a candidate for the regulation of chondrocyte hypertrophy in a previous expression profiling screen using primary micromass cultures \[[@B50]\]. The *Nr3c1*probe set which encodes the GR was up-regulated 4-fold from day 3 to day 15 of micromass culture (Figure [1A](#F1){ref-type="fig"}, top panel). Confirmation of the GR expression profile with qRT-PCR showed an approximately 8-fold increase over the same time course (Figure [1A](#F1){ref-type="fig"}, bottom panel). Studies in our laboratory and others have implicated GCs in chondrocyte differentiation and growth plate function \[[@B25],[@B26],[@B47],[@B48],[@B53],[@B54]\]. In addition, our cell counting experiments revealed that DEX consistently decreases cell numbers after 24 hrs (Figure [1B](#F1){ref-type="fig"}), in agreement with other studies that show increased apoptosis \[[@B38],[@B55]\] and reduced proliferation \[[@B56]\] in response to GCs. We therefore aimed at extending this analysis to examine pharmacological effects of GCs on growth plate chondrocytes by systematically identifying downstream effector genes of DEX. Primary chondrocytes derived from the long bones of 15.5 day old embryonic mice were treated with DEX or the vehicle control, and total RNA was isolated after 6 and 24 hrs of culture, respectively.

![**Gene expression changes in DEX-treated primary chondrocytes**. Microarray and quantitative RT-PCR expression profiles of the Glucocorticoid receptor (*Nr3c1*) in primary mesenchymal micromass cultures (A). Primary chondrocytes are plated in high density monolayers and treated with DEX or vehicle for 24 hrs and counted with a hemocytometer (B). Ordered list of global microarray data set derived from the hybridization of RNA isolated from primary chondrocytes treated with 10^-7^M DEX and the vehicle (v) control (C, left panel). One-Way ANOVA testing for significantly expressed probe sets between DEX-treated samples and the vehicle control resulted in a list of 1158 transcripts. Mean normalized signal intensities for all 1158 probe sets are shown (C, right panel). Fold change filtering of these transcripts reveal that the majority of probe sets vary in the range of 1 to 2-fold (D).](1471-2164-8-205-1){#F1}

Gene expression was evaluated using Affymetrix MOE 430 2.0 mouse genome chips using three independent cell isolations. We first analyzed gene expression using conventional analysis functions in GeneSpring GX\*. After pre-processing the data set using the GC-RMA algorithm and eliminating probe sets showing expression levels close to background, 22 091 probe sets remained, reducing the data set by 48% (Table [1](#T1){ref-type="table"}). Significance testing with one-Way ANOVA analysis identified probe sets differentially expressed between DEX and vehicle-treated cultures over the entire time course (Figure [1C](#F1){ref-type="fig"}, left panel). The resulting list contained 1158 probe sets, which is 2% of the data set\'s original size. Approximately 70% of significantly changed probe sets exhibited upregulation in response to DEX treatment. This data set was further subdivided by using 1.5-, 5- and 10- fold change filters which generated lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively (Table [1](#T1){ref-type="table"}). Examination of the overall differences between the mean normalized signal intensities associated with each condition showed minimal changes in gene expression (Figure [1C](#F1){ref-type="fig"}, right panel), indicating that GC treatment affects the expression of only a small subset of all expressed genes in this system. A distribution of fold differences between 6 and 24 hrs showed that the majority of gene expression changes did not exceed 2-fold (Figure [1D](#F1){ref-type="fig"}). In each case, both time points exhibited the same overall trends in gene expression, but, as expected, the 24 hr time point consistently showed a higher proportion of probe sets altered by DEX treatment.

###### 

Microarray analysis of DEX-treated primary chondrocyte monolayers.

  Specifications                   Probe sets at 6 hrs   Probe sets at 24 hrs
  -------------------------------- --------------------- ----------------------
  **Total number of probe sets**   **45101**             **45101**
  Significantly expressed          22091                 22091
  **Differentially expressed**     **1158**              **1158**
  1.5-fold changed                 162                   399
  **5-fold changed**               **21**                **53**
  10-fold changed                  7                     33
  **1.5-fold up-regulated**        **141**               **342**
  5-fold up-regulated              20                    50
  **10-fold up-regulated**         **7**                 **19**
  1.5-fold down-regulated          21                    57
  **5-fold down-regulated**        **1**                 **3**
  10-fold down-regulated           0                     0

Probe set validation
--------------------

To confirm the accuracy of the microarrays in identifying biologically significant differences, we selected a variety of expressed transcripts for qRT-PCR analysis (Figure [2A](#F2){ref-type="fig"}). Transcripts that either belonged to a functional class implicated in cartilage development or exhibited marked changes with DEX treatment were chosen. Markers exhibiting marginal changes in gene expression were also selected for control purposes. Specifically, we evaluated the expression patterns of Indian hedgehog (*Ihh*), Tissue inhibitor of matrix metalloproteinase 4 (*Timp4*), Cyclin-dependent kinase inhibitor 1C (*Cdkn1c*), which contains a GC response element in its promoter \[[@B57]\], Integrin beta like 1 protein (*Itgbl1*), GC receptor (*Nr3c1*), Integrin beta 1 (*Itgb1*) and Kruppel-like factor 15 (*Klf15*) over 0, 6, 12, and 24 hrs of culture with or without DEX treatment. Transcripts for *Klf15*were up-regulated from 0 to 6 hrs while *Ihh*, *Timp4*, *Cdkn1c*and *Itgbl1*all increased after the 6 hr time point. *Nr3c1*, which encodes the GR, was not affected by DEX-treatment at both 6 and 24 hrs, but does contain a putative GRE \[[@B58]\]. Transcripts such as *Itgb1*that exhibited less than 1.5-fold change in our arrays were also confirmed with qRT-PCR, providing further evidence that the microarray data represented authentic gene expression data. Interestingly, the fold change difference varied according to the experimental method. In cases such as *Timp4*and to a lesser extent *Cdkn1c*, qtPCR data showed higher fold change increases with the DEX treatment than in microarrays. In contrast, the expression pattern for *Klf15*exhibits a higher fold-change difference in the microarrays compared to the control. While data normalization using the RMA algorithm provides excellent estimates of reliable signal intensities, other methods such as the M.A.S. 5.0 algorithm are known to outperform RMA in its ability to accurately estimate fold change differences in transcript levels \[[@B59]\].

![**Identification of significantly expressed probe sets and subsequent validation with real-time RT-PCR**. Expression profiles for selected transcripts in vehicle- or DEX-treated chondrocytes are confirmed with real-time RT-PCR at 0, 6, 12 and 24 hr time points. Indian hedgehog (*Ihh*), tissue inhibitor of matrix metalloproteinase 4 (*Timp4*), cyclin-dependent kinase inhibitor 1C (*Cdkn1c*, p57), integrin beta like 1 protein (*Itgbl1*), glucocorticoid receptor (*Nr3c1*), integrin beta 1 (*Itgb1*) and kruppel-like factor 15 (*Klf15*) microarray data are shown on the left at the 6 and 24 hr time points and corresponding real-time expression values are shown on the right. P-values less than 0.01 are deemed significant. Specifically, *Ihh*, *Timp4*, *Itgbl1*and *Klf15*exhibit significant differences between the 6 and 24 hr time point and between treatments. Dotted lines indicate the control and solid lines denote DEX treatment.](1471-2164-8-205-2){#F2}

GSEA to identify the effects of dexamethasone on gene expression in chondrocytes
--------------------------------------------------------------------------------

Traditional microarray analysis methods are useful for the identification of probe sets exhibiting transcriptional responses to DEX-treatment, but are limited in certain capacities. Alternate statistical methods such as ANOVA testing produced transcript lists that, while effectively reducing the dimensionality or sample size of the data set, increased the rate of false negative data thus hampering our ability to generate meaningful hypotheses from the data (Figure [1](#F1){ref-type="fig"}). Also, the overall effect of DEX treatment on gene expression was modest, which may have reduced the significance of biologically relevant genes because their signal intensities were close to background levels. Accordingly, we did not have a clear concept of the central pathways and biological categories affected by DEX treatment. Similarly, Gene Ontology annotations were not sufficiently robust to detect differences in the representation of specific molecular categories (data not shown). We therefore implemented GSEA \[[@B52]\], an algorithm that is designed to effectively evaluate the effect of a specific experimental condition on known biological pathways and functional categories. These analyses show whether a given treatment (e.g. DEX stimulation) results in enrichment of genes sets involved in the regulation of a specific phenotype (see materials and methods for details).

We created a gene set consisting of 77 gene lists representing different tissue types, functional categories and pathways derived from other microarray studies in the literature (Table [2](#T2){ref-type="table"}). We drew conclusions from the top gene sets that had a false discovery rate (FDR) less than 25% and a p-value less than 0.001, both of which are acceptable cut-offs for the identification of biologically relevant probe sets. This cut-off, although relatively high, was optimized to reduce the occurrence of false negative data in data sets interrogating a small number of gene sets. Additionally, the FDR compensates for the inherent lack of coherence microarray data sets exhibit between gene expression and specific experimental conditions \[[@B52]\]. Enriched gene sets were identified in both DEX and vehicle data (Table [3](#T3){ref-type="table"}). Specifically, the highest statistical confidence and correlation with the DEX phenotype was assigned to metabolism and extracellular matrix, which contained 196 and 228 genes, respectively (Figure [3](#F3){ref-type="fig"}, left panels, Table [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). In each case, the expression of genes positively correlated with the DEX phenotype at the 24 hr time point exceeded the number of genes at the 6 hr time point (Figure [3](#F3){ref-type="fig"}, right panels). Metabolic genes included aldehyde and alcohol dehydrogenases (Table [4](#T4){ref-type="table"}), among others, and were identified in accordance with previously documented roles for GC in various metabolic processes and tissues \[[@B60],[@B61]\]. Closer examination of the genes contributing to the enrichment scores for the ECM gene set revealed that Dentin matrix protein 1 (*Dmp1*) was the top ranking gene (Table [5](#T5){ref-type="table"}). DMP1 belongs to the SIBLING family of matrix molecules and has been linked to chondrocyte differentiation. *Dmp1*knockout mice display disordered postnatal chondrogenesis, among other skeletal abnormalities \[[@B62]\]. Interestingly, integrin binding sialoprotein (*Ibsp*) \[[@B63]-[@B66]\]), another SIBLING family member, and osteocalcin (*Bglap2*) both contain putative GRE sequences, but did not contribute to the enrichment score for this category \[[@B63],[@B66]\]. They did, however, belong to the core group of genes that were enriched when a micromass culture gene set was used to interrogate the DEX data (Figure [4](#F4){ref-type="fig"}).

###### 

Gene sets used in GSEA.

  Category name       Number of genes   Category name          Number of genes
  ------------------- ----------------- ---------------------- -----------------
  Adipose             70                Nucleus_3              510
  Apoptosis           39                Fkbp                   33
  Bone                116               3vs15_1.5x_1           497
  Cartilage           28                3vs15_1.5x_2           497
  Catalytic           245               3vs15_1.5x_3           497
  Chaperone           81                3vs15_1.5x_4           497
  Chemokine           31                3vs15_1.5x_5           76
  Chromatin/Hdacs     24                Igf                    48
  Cyclin              225               Cart_2                 299
  Cytokine            127               Cart_3                 352
  1_Dnabind           500               Liver_1                260
  2_Dnabind           448               Liver_2                260
  Ecm                 228               Blood                  111
  Electron_Transp     40                Protease_1             269
  Gf Receptor         327               Protease_2             269
  Gluconeogen         31                Phosphatase            473
  Growth Factor       106               Dusp                   20
  Gtpase Activator    46                Kinase_1               499
  Gtpase Activ        73                Kinase_2               499
  Heparin Bind        37                Kinase_3               227
  Hormone             75                Integrin_Rel           173
  Muscle              198               Brain_Rel              379
  Neg_Apoptosis       50                Hepatocyte             19
  Oncogene            154               Obl_Oclast             16
  Pos_Apoptosis       79                Interleukinrelated     175
  Related_Apoptosis   311               Rgs_Related            44
  Structure           151               Caspase_Related        47
  Sugar_Bind          104               Creb_Atf3              32
  Tf_Activ            56                Nuclear Receptor       138
  Tf_Repress          55                Nuc_Hormone_Receptor   55
  Tgfb                45                Mapkrelated            267
  Tnf_Receptor        69                Membrane               260
  Tumor Suppressor    48                Metabolism             196
  Wnt                 53                Nucleus_1              494
  Actin_Cytoskel      38                Nucleus_2              494
  Angiogen            57                Pzhorton.Farnum        413
  Bmprelated          62                Hzhorton.Farnum        407
  Cytoplasm           411                                      
  Erk_Related         40                                       
  Fgf_Related         64                                       

###### 

GSEA of DEX-treated primary chondrocytes.

  Gene set name          Size   ES       NES     NOM p-val   FDR q-val
  ---------------------- ------ -------- ------- ----------- -----------
  Metabolism             196    0.471    1.935   \<0.001     0.016
  Extracellualr Matrix   228    0.451    1.878   \<0.001     0.016
  Fkbp                   33     0.559    1.696   0.011       0.054
  Integrin_Related       173    0.407    1.643   \<0.001     0.001
  Angiogenesis           57     0.479    1.610   0.012       0.065
  Kinase_1               499    0.343    1.549   \<0.001     0.092
  Tumor Suppressor       48     0.457    1.492   0.037       0.126
  Catalytic              245    0.337    1.420   0.008       0.172
  Hepatocyte             19     0.529    1.406   0.104       0.161
  D3 Vs D15_2            497    0.304    1.368   0.004       0.194
  Igf                    48     0.412    1.348   0.093       0.208
  Cyclin                 224    0.322    1.344   0.028       0.199
  Actin_Cytoskel         38     0.426    1.325   0.124       0.213
  Structure              151    0.332    1.312   0.053       0.219
  Cytoplasm              411    0.292    1.300   0.023       0.224
  Adipose                70     0.368    1.285   0.116       0.232
  Gtpase Activity        73     0.363    1.280   0.113       0.230
  Cartilage              28     0.432    1.262   0.169       0.246
  Chemokine              31     -0.779   -2.40   \<0.001     0
  Cytokine               127    -0.579   -2.31   \<0.001     0
  Growth Factor          106    -0.517   -2.01   \<0.001     7.698E-04
  Interleukinrelated     175    -0.469   -1.98   \<0.001     9.475E-04
  Bone                   16     -0.577   -1.51   0.051       8.945E-02
  Creb_Atf3              30     -0.469   -1.43   0.065       1.300E-01
  Dusp                   20     -0.508   -1.40   0.102       1.418E-01
  Blood                  111    -0.351   -1.37   0.037       1.425E-01
  3vs15_1.5x_3           496    -0.288   -1.35   0.002       1.518E-01
  Protease_2             268    -0.306   -1.35   0.015       1.411E-01
  Nuc_Hormone_Receptor   55     -0.381   -1.32   0.086       1.570E-01
  Tf_Repress             55     -0.380   -1.32   0.091       1.498E-01
  3vs15_1.5x_4           497    -0.272   -1.28   0.011       1.817E-01
  Erk_Related            40     -0.385   -1.25   0.157       2.169E-01

ES, enrichment score

NES, normalized enrichment score

FDR q-val, false discovery rate and multiple testing corrections (q-value)

NOM p-val; the uncorrected p-value

###### 

Metabolic transcripts enriched in DEX-treated chondrocytes. I.

  HUGO symbol     Rank   RMS\*   RES\*\*   HUGO symbol     Rank   RMS\*   RES\*\*
  --------------- ------ ------- --------- --------------- ------ ------- ---------
  Aldh1a1         26     0.417   0.053     Slc27a4         1616   0.058   0.426
  Eya2            40     0.355   0.099     Ltbp2           1721   0.056   0.428
  Vcl             106    0.228   0.125     Hsd17b1         1783   0.055   0.432
  Adhfe1          116    0.222   0.154     P4ha2           1783   0.055   0.432
  Ids             123    0.212   0.181     Mut             1850   0.053   0.443
  Cbr3            133    0.204   0.207     Pde3a           2195   0.048   0.432
  Aldh6a1         202    0.165   0.225     Sulf2           2200   0.048   0.438
  Bcat2           224    0.157   0.245     Prep            2316   0.046   0.438
  Pmm1            278    0.145   0.261     Plod3           2387   0.045   0.441
  Pcx             553    0.105   0.261     1110013G13RIK   2510   0.043   0.440
  Fthfd           554    0.105   0.275     Pld1            2669   0.041   0.437
  Atp1a1          560    0.104   0.288     Au041707        2721   0.040   0.440
  Gstm1           619    0.099   0.298     Decr1           2837   0.039   0.439
  Gstm2           742    0.088   0.303     Gstm5           2872   0.038   0.443
  1700061G19RIK   787    0.086   0.312     Bckdha          2932   0.038   0.445
  Slc38a4         833    0.084   0.321     Atp11a          2951   0.038   0.449
  Pyp             847    0.083   0.331     Gstp1           2967   0.037   0.453
  Aacs            901    0.080   0.339     Dhrs7           3014   0.037   0.455
  Plod1           934    0.079   0.348     Cbr2            3147   0.035   0.453
  Acas2           983    0.077   0.355     Echdc3          3152   0.035   0.458
  Auh             1068   0.074   0.361     Acy3            3254   0.035   0.457
  Gcat            1109   0.072   0.368     Dhrs1           3483   0.032   0.450
  Dhrs8           1184   0.070   0.373     Itgb1           3527   0.032   0.452
  Egln3           1232   0.068   0.380     4933406E20RIK   3553   0.031   0.454
  Mthfs           1268   0.067   0.387     Plod2           3574   0.031   0.458
  Mvk             1298   0.066   0.394     Pmm2            3582   0.031   
  Aup1            1325   0.065   0.401     Ugp2            3583   0.031   
  Spr             1456   0.062   0.403     Gnpat           3633   0.031   
  Sc5dl           1462   0.062   0.411     1110003P22RIK   3636   0.031   
  1300018J18RIK   1516   0.061   0.416     Dbt             3710   0.030   
  Agpat3          1524   0.061   0.423                                    

Rank = position of genes in the context of the ranked list of array genes

RMS = the ranked metric score

RES = the running enrichment score

###### 

ECM-related transcripts enriched in DEX-treated chondrocytes.

  HUGO symbol   Rank   RMS     RES     HUGO symbol     Rank   RMS\*   RES\*\*
  ------------- ------ ------- ------- --------------- ------ ------- ---------
  Dmp1          18     0.470   0.036   Matn4           882    0.081   0.420
  Omd           27     0.409   0.068   Lama3           886    0.081   0.427
  Itga5         38     0.358   0.095   Nyx             992    0.077   0.427
  Adamts1       57     0.305   0.118   Lamb2           1082   0.073   0.429
  Timp4         61     0.296   0.141   Bsg             1100   0.072   0.433
  Col4a1        86     0.268   0.161   Fbn2            1242   0.068   0.432
  Col4a2        98     0.247   0.180   Ntn4            1245   0.068   0.437
  Adam12        112    0.225   0.197   5730577E14RIK   1381   0.064   0.435
  Prelp         139    0.200   0.211   Col6a2          1405   0.064   0.439
  Postn         142    0.195   0.227   Ntn3            1415   0.063   0.443
  Chad          176    0.174   0.239   Tgfb2           1531   0.060   0.442
  Mgp           195    0.168   0.251   Mia1            1575   0.059   0.445
  Col1a1        232    0.154   0.261   Mmp14           1803   0.054   0.438
  Mfap5         233    0.153   0.273   Col15a1         1845   0.053   0.440
  Col10a1       266    0.146   0.283   Ctgf            1882   0.052   0.442
  Smoc2         279    0.145   0.294   Col6a1          1942   0.052   0.443
  Aspn          294    0.141   0.304   Gpld1           1946   0.051   0.447
  Col4a5        367    0.128   0.310   Emid2           2043   0.050   0.446
  Adamts15      385    0.126   0.319   Col7a1          2047   0.050   0.450
  Tgfb1         394    0.125   0.329   Adam10          2107   0.049   0.451
  Sparcl1       440    0.119   0.336   Col9a2          605    0.100   0.370
  Adam17        483    0.112   0.343   Matn3           610    0.099   0.377
  Lama5         508    0.110   0.350   Col11a2         636    0.097   0.384
  Lamc1         517    0.109   0.358   Hapln1          650    0.096   0.391
  Spock2        581    0.102   0.363   Lama2           685    0.092   0.396
  Lama1         688    0.092   0.403   Gpc3            796    0.086   0.412
  Ltbp4         704    0.091   0.410   Lama4           827    0.084   0.417

\*RMS = the ranked metric score

\*\*RES = the running enrichment score

![**Enrichment plots for statistically significant gene sets identified by GSEA**. User-defined gene sets enriched with the DEX or vehicle conditions are depicted. Black bars illustrate the position of probe sets belonging to metabolic, extracellular matrix (A), cytokine and growth factor (B) gene sets in the context of all probes on the DEX array. The running enrichment score (RES) plotted as a function of the position within the ranked list of array probes is shown in green. The ranked list metric shown in gray illustrates the correlation between the signal to noise values of all individually ranked genes according and the class labels (experimental conditions). Metabolic and ECM genes are overrepresented in the left side of the enrichment plot indicating correlation to differential expression in DEX-treated chondrocytes. In contrast, cytokines and growth factor genes are enriched in the right side of the plots and correspond to the vehicle control. Significantly enriched data sets are defined according to GSEA default settings i.e., a p \< 0.001 and a false discovery rate (FDR) \< 0.25. Individual expression profiles for probe sets contributing to the normalized enrichment score are shown in the right panel. R.L.M = ranked list metric, E.S. = enrichment score.](1471-2164-8-205-3){#F3}

![**Comparison of DEX-treated primary chondrocytes to a time course of chondrocyte differentiation in micromass culture**. The Venn diagram depicts probe sets that are common between the list of 2119 probe sets differentially expressed between days 3 and 15 of micromass culture and the list of 22 091 significantly expressed probe sets in primary chondrocyte monolayer cultures (A). The matrix of 77 user-defined gene sets are used to interrogate microarray data from days 15 and day 3 of micromass culture. Normalized enrichment scores (NES) generated from this analysis are then compared to NES scores derived from the DEX study to evaluate similarities in the regulation of different groups of genes in chondrocytes (B). Positive enrichment scores (ES) indicate gene sets that are enriched and up-regulated in DEX-treated chondrocytes or d15 of micromass culture. Negative ES indicate gene set enrichment and down-regulation in the DEX-treatment or up-regulation in the day 3 samples of the micromass (MM) culture data set.](1471-2164-8-205-4){#F4}

Osteomodulin, an additional matrix molecule shown to be structurally similar to IBSP \[[@B67]\], ranked second in the list of enriched ECM genes. Additional ECM molecules expressed in terminally differentiated chondrocytes such as collagen 10 (*Col10a1*) and osteonectin (*Spock1*) were identified, suggesting that this molecular classification is important for transmitting GC signaling in the growth plate.

Interestingly, the normalized enrichment scores for factors down-regulated by DEX treatment were higher than those positively correlated with DEX, but contained fewer probe sets contributing to the scores. Gene sets composed of 127 and 106 genes associated with cytokine and growth factor activity, respectively, were negatively correlated with DEX treatment (Figure [4](#F4){ref-type="fig"}, Table [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}). In other studies, cytokines such as Il-8 and GROα were found to promote the hypertrophy of osteoarthritic cartilage, and excess interleukins 1β(IL-1β), interleukin 6 (IL-6) and Tumor Necrosis Factor alpha (TNF-α) cause growth failure in children \[[@B68]-[@B70]\]. Our studies identified three members of the GP-130 family of cytokines, namely interleukins -11,-6 (*Il11, Il6*) and leukemia inhibitory factor (*Lif*), as part of the core enrichment group for cytokines (Table [6](#T6){ref-type="table"}). Transgenic mice overexpressing Il-6 exhibit growth retardation, and LIF is thought to regulate the rate at which terminally differentiated cartilage is calcified and vascularized \[[@B71],[@B72]\].

###### 

Cytokine transcripts enriched in vehicle-treated chondrocytes. I.

  HUGO gene symbol   Rank    RMS       RES
  ------------------ ------- --------- --------
  Cklfsf2b           16971   -0.0424   -0.574
  Il7                16981   -0.0425   -0.569
  Il1f9              17007   -0.0427   -0.566
  Grn                17130   -0.0439   -0.567
  Il1f6              17153   -0.0442   -0.563
  Ifna2              17418   -0.0468   -0.571
  Tslp               17503   -0.0477   -0.570
  Il17               17568   -0.0483   -0.568
  A730028g07rik      17606   -0.0486   -0.564
  Cxcl11             17634   -0.0490   -0.560
  Ctf1               17857   -0.0519   -0.565
  Lta                17864   -0.0519   -0.559
  Il1a               18018   -0.0539   -0.561
  Ccl20              18038   -0.0542   -0.556
  Ccl17              18334   -0.0584   -0.564
  Ccl12              18384   -0.0592   -0.560
  Cklf               18618   -0.0639   -0.564
  Ifna11             18855   -0.0688   -0.568
  Cklfsf6            18874   -0.0693   -0.561
  Il15               18955   -0.0719   -0.557
  Ltb                19146   -0.0779   -0.558
  Ccl3               19220   -0.0814   -0.552
  Tnfsf9             19228   -0.0816   -0.543
  Cx3cl1             19523   -0.0975   -0.547
  Gdf15              19660   -0.1100   -0.541
  Bmp5               19775   -0.1238   -0.533
  Cxcl14             19798   -0.1289   -0.519
  Cxcl1              19928   -0.1698   -0.507
  Cxcl10             19951   -0.1807   -0.487
  Ccl7               19956   -0.1849   -0.466
  Gdf5               19973   -0.2066   -0.444
  Cxcl12             19978   -0.2104   -0.420
  Areg               19983   -0.2189   -0.395
  Cxcl2              19996   -0.2421   -0.369
  Ppbp               20014   -0.2944   -0.336
  Lif                20024   -0.3296   -0.299
  Ccl2               20030   -0.3589   -0.258
  Il11               20035   -0.4036   -0.213
  Cxcl5              20039   -0.5406   -0.152
  Tnfsf11            20041   -0.5835   -0.085
  Il6                20043   -0.7529   

Rank = position of genes in the context of the ranked list of array genes

RMS = the ranked metric score

RES = the running enrichment score

###### 

Growth factor transcripts vehicle in DEX-treated chondrocytes.

  HUGO gene symbol   Rank    RMS      RES
  ------------------ ------- -------- --------
  Fgf21              18968   -0.073   -0.508
  Nrg3               19132   -0.077   -0.506
  Fgf5               19190   -0.080   -0.499
  Ereg               19507   -0.096   -0.502
  Fgf7               19581   -0.102   -0.493
  Gdf15              19660   -0.110   -0.483
  Igf1               19679   -0.111   -0.469
  Bmp5               19775   -0.124   -0.458
  Nov                19848   -0.144   -0.443
  Vegf               19877   -0.150   -0.425
  Ptn                19885   -0.153   -0.406
  Cxcl1              19928   -0.170   -0.386
  Bdnf               19939   -0.176   -0.364
  Inhba              19971   -0.204   -0.340
  Gdf5               19973   -0.207   -0.313
  Cxcl12             19978   -0.210   -0.287
  Areg               19983   -0.219   -0.259
  Hbegf              20006   -0.264   -0.226
  Ngfb               20013   -0.287   -0.189
  Lif                20024   -0.330   -0.148
  Il11               20035   -0.404   -0.096
  Il6                20043   -0.753   0.000

Rank = position of genes in the context of the ranked list of array genes

RMS = the ranked metric score

RES = the running enrichment score

This group also contained the gene encoding Tumor necrosis factor (ligand) superfamily, member 11 (*Tnfsf11*, RANKL), which has been localized to mature chondrocytes and is thought to promote degradation of the calcified cartilage ECM and ultimately endochondral ossification through activation of osteoclasts \[[@B73]-[@B75]\]. It is important to note that several independent gene sets connected to inflammation such as cytokines, chemokines and interleukins exhibit some overlap and showed similar enrichment patterns, which provides additional confirmation that DEX is indeed downregulating inflammatory molecules in chondrocytes. GC have been previously reported to down-regulate the expression of VEGF, one of the central growth factors involved in vascularization of calcified cartilage matrix \[[@B49]\], in agreement with our data (Table [7](#T7){ref-type="table"}). Since some of these factors, such as RANKL, VEGF and LIF, promote normal tissue remodeling processes during endochondral ossification, our data suggest that DEX prevents the replacement of hypertrophic cartilage by bone. GC have been shown to delay chondrocyte maturation while retaining their capacity to re-engage in their developmental program \[[@B21]\]. This could account for upregulation of genes typically associated with the chondrocyte phenotype, such as ECM genes and the coordinated downregulation of factors that promote the transition from cartilage into bone.

Identification of cartilage-specific dexamethasone-effects
----------------------------------------------------------

Identification of cartilage-specific gene sets affected by DEX treatment provided further insight into the complex nature of GC functions in cartilage. We knew from other studies that DEX effects on chondrogenic differentiation are dependent on cell source, experimental system and DEX concentration \[[@B40],[@B42],[@B76]-[@B78]\]. We aimed to systematically characterize the effects of DEX on growth plate chondrocytes. To ensure that our DEX data set was expressing bona fide cartilage markers, we compared the DEX data to our previously generated micromass culture data set \[[@B50]\]. We compared all expressed probe sets in the DEX array to probe sets exhibiting a minimum 1.5-fold change in expression between days 3 and 15 of micromass cultures that encompass the various stages of the chondrocyte life cycle. Day 3 of micromass culture likely coincides with the onset of the cartilage developmental program and early chondrogenesis. After 15 days of culture, the cell population is comprised primarily of terminally differentiated chondrocytes and thus corresponds mostly to the hypertrophic zone of the growth plate \[[@B50],[@B79]\], although small numbers of other cells are present at all stages. Out of the 2119 probe sets displaying at least 1.5-fold changes in expression in the micromass culture data set (a probe set list generated from the pair-wise comparison of day 3 versus day 15 of micromass culture), 1730 were also expressed in the DEX array. This shows that our primary chondrocyte monolayers do exhibit prototypical chondrocyte gene expression patterns in both the presence and absence of DEX treatment.

To complete more robust classification of the data in which we could correlate chondrocyte gene expression to the DEX phenotype, we created a gene set from this list of 2119 probe sets (Table [8](#T8){ref-type="table"}, [9](#T9){ref-type="table"}). The micromass derived gene list was enriched in this study; however, the list was found to correlate both positively and negatively with different aspects of the DEX phenotype. We therefore proceeded to evaluate both the micromass (MM) data set and the DEX data set using GSEA analysis and the previously created gene sets. If both the micromass time course and the DEX data sets show the same enrichment pattern, we would have evidence to suggest that pharmacological DEX doses promote chondrocyte differentiation. Normalized enrichment scores for gene sets common to both culture methods were therefore compared to identify differences and similarities between DEX-treated chondrocytes and the chondrocyte phenotype (Figure [4B](#F4){ref-type="fig"}).

###### 

Micromass culture-derived gene sets are enriched in DEX-treated primary chondrocytes (d3 vs d15_2). I.

  HUGO gene symbol   Rank   RMS     RES
  ------------------ ------ ------- -------
  Itgbl1             32     0.391   0.015
  Adrb2              54     0.308   0.026
  Bst1               80     0.271   0.036
  Gpx3               83     0.269   0.047
  Myocd              90     0.259   0.058
  Grk5               105    0.229   0.066
  Ids                123    0.212   0.074
  Ms4a6b             140    0.200   0.082
  1810057c19rik      146    0.193   0.090
  Igfbp2             149    0.190   0.097
  Zfp36              218    0.159   0.100
  Serpina3n          222    0.158   0.107
  P2ry6              225    0.157   0.113
  Adm                228    0.156   0.120
  Crym               277    0.145   0.123
  Ppap2a             303    0.139   0.128
  Pycard             307    0.138   0.133
  Kcns1              320    0.134   0.138
  Cd80               321    0.134   0.144
  Trim24             330    0.133   0.149
  C1qtnf6            339    0.131   0.154
  A330049m08rik      377    0.127   0.157
  Adamts15           385    0.126   0.162
  Elovl4             398    0.124   0.167
  C1qa               402    0.124   0.172
  Sox9               434    0.119   0.175
  Htra3              455    0.116   0.179
  Adam17             483    0.112   0.182
  Mgll               493    0.112   0.186
  Ibsp               507    0.110   0.190
  C1qb               511    0.109   0.194
  Bambi              516    0.109   0.199
  Anxa4              551    0.105   0.201
  Cd109              555    0.105   0.206
  Nrk                559    0.104   0.210
  Gstm1              619    0.099   0.211
  Asb4               634    0.097   0.214
  Pygl               654    0.095   0.217
  Rasl11b            655    0.095   0.221
  Cdc42ep4           674    0.093   0.224
  Slc9a3r2           683    0.092   0.227
  Lama1              688    0.092   0.231
  Bb146404           707    0.091   0.234
  Ai194308           724    0.090   0.237
  Smn1               752    0.088   0.239
  Alcam              772    0.087   0.242
  Cst3               790    0.086   0.244
  Pyp                847    0.083   0.245
  2700017m01rik      870    0.082   0.247
  Fgfr3              884    0.081   0.250
  Mrpl34             912    0.080   0.252
  C9orf46            972    0.077   0.252
  Maf                981    0.077   0.255
  8430420c20rik      1028   0.075   0.255
  Gfm2               1030   0.075   0.259
  Anxa6              1041   0.075   0.261
  Isg20              1064   0.074   0.263
  Auh                1068   0.074   0.266
  Bsg                1100   0.072   0.267
  Peg3               1179   0.070   0.266
  Adam23             1208   0.069   0.268
  Ezh1               1213   0.069   0.270
  2810022l02rik      1214   0.069   0.273
  0610011i04rik      1248   0.068   0.274
  Pbx2               1257   0.067   0.277
  Jup                1291   0.066   0.278
  Zcwcc2             1301   0.066   0.280
  Whsc2              1317   0.066   0.282
  2410004l22rik      1344   0.065   0.283
  Lmnb2              1388   0.064   0.284
  Fndc1              1435   0.063   0.284
  Rarres2            1460   0.062   0.285
  Tap2               1512   0.061   0.285
  Ctbs               1559   0.060   0.285
  Jdp2               1574   0.059   0.287
  Hck                1712   0.056   0.282
  5031400m07rik      1792   0.054   0.281
  Pkn1               1839   0.053   0.280
  Dag1               1929   0.052   0.278
  Fth1               1976   0.051   0.278
  1110001e17rik      1979   0.051   0.280
  Rbp4               1984   0.051   0.282
  Pdcd6ip            2044   0.050   0.281
  Siat7d             2050   0.050   0.283
  Kcnd2              2074   0.050   0.284
  2310004k06rik      2076   0.050   0.286
  D19ertd678e        2106   0.049   0.286
  Npdc1              2114   0.049   0.288
  Fts                2116   0.049   0.290
  Prickle1           2123   0.049   0.291
  1110037f02rik      2171   0.048   0.291
  Cdc42se1           2246   0.047   0.289
  Chpt1              2261   0.047   0.290
  Wwp2               2341   0.045   0.288
  Dact1              2363   0.045   0.289
  Rragd              2380   0.045   0.290
  Irf5               2406   0.044   0.291
  Nrbf2              2414   0.044   0.292
  Cox4i2             2436   0.044   0.293
  Bmp7               2456   0.044   0.294
  1810008a18rik      2517   0.043   0.292
  Asph               2533   0.043   0.293
  Stat2              2550   0.042   0.294
  Hoxa11             2560   0.042   0.296
  Bax                2599   0.042   0.295
  Sspn               2611   0.042   0.297
  Ifngr2             2612   0.042   0.298
  Glrx1              2672   0.041   0.297
  Gba                2739   0.040   0.295
  Fzd2               2759   0.040   0.296
  Crtap              2772   0.040   0.297
  Slc1a5             2786   0.040   0.298
  Slco3a1            2831   0.039   0.297
  3110040n11rik      2833   0.039   0.299
  Tep1               2845   0.039   0.300
  Fastk              2860   0.039   0.301
  Tmed3              2869   0.038   0.302
  Ephb4              2876   0.038   0.303
  Asah2              2908   0.038   0.303
  Pold4              2989   0.037   0.301
  1110001a07rik      2995   0.037   0.302
  Pcp4               3010   0.037   0.303
  Mab21l2            3025   0.037   0.304

Rank = position of genes in the context of the ranked list of array genes

RMS = the ranked metric score

RES = the running enrichment score

###### 

Micromass culture-derived transcripts enriched in vehicle-treated primary chondrocytes (d3 vs d15_3/4). I.

  HUGO gene symbol   Rank    RMS      RES
  ------------------ ------- -------- --------
  Rabggtb            16734   -0.040   -0.271
  Ube2e2             16759   -0.041   -0.270
  Cd68               16769   -0.041   -0.269
  H2-T23             16830   -0.041   -0.270
  Derl1              16834   -0.041   -0.268
  Smarcc1            16853   -0.041   -0.267
  Srxn1              16856   -0.041   -0.266
  Klf10              16868   -0.042   -0.264
  Zfhx1b             16879   -0.042   -0.263
  H2afy3             16929   -0.042   -0.264
  Wisp2              16973   -0.042   -0.264
  Tbl1xr1            16976   -0.042   -0.262
  Ppp1r3c            16979   -0.042   -0.260
  D11lgp2e           17036   -0.043   -0.261
  Smpdl3b            17079   -0.043   -0.262
  Dock2              17125   -0.044   -0.262
  Purb               17127   -0.044   -0.260
  Grn                17130   -0.044   -0.258
  1110035l05rik      17139   -0.044   -0.257
  Kiaa1008           17185   -0.045   -0.257
  E430025l02rik      17195   -0.045   -0.256
  Timm8a             17293   -0.046   -0.259
  C130006e23         17307   -0.046   -0.257
  Rbm10              17319   -0.046   -0.256
  A230103n10rik      17347   -0.046   -0.255
  Cd151              17401   -0.047   -0.256
  Srf                17409   -0.047   -0.254
  Cacna1s            17507   -0.048   -0.257
  Ythdf1             17529   -0.048   -0.256
  Ppp2r1b            17539   -0.048   -0.254
  Tead2              17545   -0.048   -0.252
  Igsf7              17590   -0.049   -0.252
  Per3               17604   -0.049   -0.251
  G1p2               17739   -0.050   -0.256
  Slco2a1            17786   -0.051   -0.256
  Coq7               17918   -0.053   -0.260
  Rarb               17940   -0.053   -0.259
  Lcp1               17954   -0.053   -0.257
  Dnaja1             17987   -0.053   -0.256
  Thoc3              17993   -0.054   -0.254
  Cd44               18041   -0.054   -0.254
  Slc41a1            18171   -0.056   -0.258
  Kif11              18232   -0.057   -0.259
  Hspa5bp1           18235   -0.057   -0.257
  Ncf4               18290   -0.058   -0.257
  Bub1b              18292   -0.058   -0.254
  Cap2               18295   -0.058   -0.252
  Aig1               18340   -0.059   -0.251
  Rfc3               18361   -0.059   -0.250
  Stmn1              18396   -0.060   -0.249
  9130213b05rik      18408   -0.060   -0.247
  Tyms-Ps            18432   -0.060   -0.245
  Timp3              18513   -0.062   -0.247
  Tiparp             18564   -0.063   -0.247
  Thbs4              18627   -0.064   -0.247
  Wasf1              18652   -0.064   -0.245
  Nupr1              18686   -0.065   -0.244
  Ezh2               18706   -0.066   -0.242
  Fbxl14             18709   -0.066   -0.239
  Prim1              18780   -0.067   -0.240
  Insig2             18805   -0.068   -0.238
  B3gnt5             18858   -0.069   -0.238
  Fam60a             18963   -0.072   -0.240
  H2-M3              18972   -0.073   -0.237
  Gja7               18974   -0.073   -0.234
  Bex2               18987   -0.073   -0.231
  Tk1                19043   -0.074   -0.231
  1200015n20rik      19109   -0.076   -0.231
  Clecsf5            19114   -0.077   -0.228
  Ms4a7              19141   -0.078   -0.226
  Cdca5              19163   -0.079   -0.223
  C730042f17rik      19180   -0.079   -0.220
  Trim25             19194   -0.080   -0.218
  Efnb2              19207   -0.081   -0.215
  Apex1              19236   -0.082   -0.212
  Ddah2              19243   -0.082   -0.209
  Bub1               19262   -0.083   -0.206
  Nup43              19263   -0.083   -0.203
  Rdh10              19270   -0.083   -0.199
  2610201a13rik      19330   -0.086   -0.199
  Rp2h               19406   -0.089   -0.198
  Tnni1              19407   -0.089   -0.195
  Myog               19423   -0.091   -0.191
  Osmr               19486   -0.095   -0.190
  Mmp9               19524   -0.097   -0.188
  Tnnt1              19525   -0.098   -0.184
  Fhod3              19528   -0.098   -0.179
  D930038m13rik      19537   -0.099   -0.175
  Nes                19567   -0.101   -0.172
  Sbk1               19571   -0.102   -0.168
  Dusp9              19594   -0.103   -0.165
  Akr1b8             19622   -0.106   -0.161
  Pdgfrb             19663   -0.110   -0.158
  Tfrc               19667   -0.111   -0.154
  Moxd1              19670   -0.111   -0.149
  1810008k03rik      19681   -0.112   -0.145
  Cpeb1              19710   -0.115   -0.141
  6720475j19rik      19716   -0.116   -0.136
  Ripk4              19718   -0.116   -0.131
  Itga6              19756   -0.121   -0.127
  Bmp5               19775   -0.124   -0.123
  Lhx9               19776   -0.124   -0.117
  Pkp2               19797   -0.129   -0.113
  Chrna1             19808   -0.131   -0.108
  Bhlhb2             19837   -0.142   -0.103
  Gp49a              19847   -0.144   -0.097
  Clecsf10           19893   -0.155   -0.092
  Gch1               19902   -0.159   -0.086
  D0h4s114           19908   -0.161   -0.079
  Cxcl1              19928   -0.170   -0.072
  Ch25h              19946   -0.178   -0.065
  Mkrn3              19988   -0.228   -0.057
  Ptprc              20016   -0.297   -0.046
  Car6               20017   -0.298   -0.032
  Nr1d2              20031   -0.368   -0.017
  Evi2a              20033   -0.393   0.001
  Plxnc1             18075   -0.055   -0.286
  Cilp2              18106   -0.055   -0.285
  Brca1              18148   -0.056   -0.285
  Litaf              18149   -0.056   -0.283
  Bc027246           18154   -0.056   -0.281
  6820424l24rik      18268   -0.057   -0.285
  Hrb                18272   -0.057   -0.283
  Nnat               18303   -0.058   -0.282
  P2ry12             18329   -0.058   -0.282
  Cdca4              18343   -0.059   -0.280
  6030404e16rik      18367   -0.059   -0.279
  Tfec               18429   -0.060   -0.280
  Nfe2l2             18440   -0.060   -0.278
  Gtf2h2             18467   -0.061   -0.277
  4930469p12rik      18504   -0.062   -0.277
  Cul4b              18535   -0.062   -0.276
  H2afy2             18547   -0.063   -0.274
  1190002n15rik      18582   -0.063   -0.274
  B430218l07rik      18591   -0.063   -0.272
  Rgs18              18607   -0.064   -0.270
  Frk                18631   -0.064   -0.269
  Slc6a9             18633   -0.064   -0.267
  Tgfbr2             18687   -0.065   -0.267
  Tia1               18802   -0.068   -0.270
  Lgr5               18844   -0.068   -0.270
  Sgpp1              18909   -0.071   -0.271
  Matn2              18924   -0.071   -0.269
  Sox11              18931   -0.071   -0.266
  Hus1               18980   -0.073   -0.266
  D930015e06rik      19028   -0.074   -0.266
  Apob48r            19032   -0.074   -0.263
  Av344025           19045   -0.074   -0.261
  Eno2               19047   -0.074   -0.258
  2610024e20rik      19053   -0.075   -0.256
  Chd1l              19093   -0.076   -0.255
  Emr1               19145   -0.078   -0.255
  Rgs4               19200   -0.081   -0.254
  D030028o16rik      19211   -0.081   -0.252
  Kif2c              19216   -0.081   -0.249
  Ccl3               19220   -0.081   -0.246
  Trim30             19232   -0.082   -0.244
  Qrsl1              19242   -0.082   -0.241
  Nr3c1              19281   -0.083   -0.240
  Trip13             19282   -0.084   -0.237
  Dna2l              19317   -0.085   -0.236
  Tcf8               19335   -0.086   -0.233
  Clecsf8            19341   -0.086   -0.230
  Lyzs               19422   -0.090   -0.231
  Palmd              19475   -0.095   -0.230
  Tjp2               19487   -0.095   -0.227
  D430019h16rik      19493   -0.096   -0.224
  Sesn3              19501   -0.096   -0.221
  Ereg               19507   -0.096   -0.218
  Cx3cl1             19523   -0.097   -0.215
  Fzd6               19529   -0.098   -0.211
  Sod3               19564   -0.101   -0.209
  Tnnt2              19580   -0.102   -0.206
  Satb1              19599   -0.104   -0.203
  Cd14               19606   -0.104   -0.200
  Gbp2               19607   -0.104   -0.196
  Tgfbi              19609   -0.105   -0.192
  Chek1              19652   -0.109   -0.190
  Tm4sf1             19653   -0.109   -0.186
  Igf1               19679   -0.111   -0.183
  Enpp1              19695   -0.113   -0.180
  Slc15a3            19704   -0.114   -0.176
  Pdpn               19725   -0.117   -0.173
  Dkk1               19747   -0.119   -0.169
  Slk                19759   -0.121   -0.166
  Ankrd1             19794   -0.128   -0.163
  Trp53bp1           19801   -0.129   -0.158
  C79407             19804   -0.130   -0.153
  2210010l05rik      19809   -0.131   -0.149
  Eps8               19815   -0.133   -0.144
  Dkk2               19862   -0.147   -0.141
  Arhgap18           19863   -0.147   -0.136
  Twist2             19878   -0.151   -0.131
  Pcdha8             19915   -0.164   -0.126
  Il4r               19926   -0.169   -0.121
  Mdm1               19931   -0.172   -0.115
  Phlda1             19957   -0.188   -0.109
  Bhlhb5             19960   -0.192   -0.102
  C130076o07rik      19964   -0.196   -0.095
  5830411e10rik      19974   -0.207   -0.088
  Ptpre              19989   -0.228   -0.080
  Trib3              19990   -0.235   -0.071
  9230117n10rik      19994   -0.241   -0.062
  Pcdhb7             19998   -0.249   -0.053
  Mmp3               20001   -0.252   -0.044
  Cd34               20009   -0.274   -0.034
  Thbd               20022   -0.310   -0.023
  A830016g23rik      20023   -0.323   -0.011
  Ahr                20028   -0.336   0.001

Rank = position of genes in the context of the ranked list of array genes

RMS = the ranked metric score

RES = the running enrichment score

Four different patterns were observed when comparing DEX treatment and micromass differentiation data sets for gene enrichments scores (Figure [4B](#F4){ref-type="fig"}). First, similar gene sets were indeed enriched in both day 15 micromass and DEX-treated monolayer cultures, and core genes contributing to the normalized enrichment scores were similarly overlapping between the two data sets in results with low FDR. For example, ECM genes were enriched with both DEX treatment and the day 15 micromass phenotype. Other gene sets following this enrichment pattern included genes involved in integrin function, angiogenesis, catalytic activity, IGF related, adipocyte and cartilage, all of which have a precedent for being involved in chondrocyte maturation \[[@B28],[@B49],[@B80],[@B81]\]. The enrichment of angiogenic transcripts with DEX treatment was unexpected since DEX was shown to have anti-angiogenic roles in cartilage; however, upon closer examination of the genes contributing to the enrichment score, *Vegf*, which is thought to be a central angiogenic factor in endochondral ossification \[[@B82]\], was excluded from the core enrichment genes and had the lowest correlation with the DEX phenotype in that gene set. In contrast, *Vegf*was enriched in the growth factor data set which positively correlated with the vehicle control and not DEX treatment (Table [7](#T7){ref-type="table"}).

Gene sets associated with the actin cytoskeleton, tumour suppressors, structure, cytoplasmic genes, hepatocyte markers and dual specificity phosphatases (DUSPs) were enriched in the DEX data set and the phenotype positively correlated with day 3 of micromass culture. The identification of DUSPs was particularly interesting since DEX has been shown to induce genes encoding for these proteins \[[@B77],[@B83],[@B84]\]. DUSPS counteract the activation of MAP kinase pathways, known regulators of chondrocyte differentiation \[[@B85]\], and are thought to mediate DEX\'s anti-inflammatory functions and to influence hepatic gluconeogenesis \[[@B83],[@B86],[@B87]\].

Additional comparisons identified genes that show enrichment in day 15 micromass cultures and downregulation with DEX treatment. These include the previously identified chemokines, cytokines and interleukins. A final trend in similarly enriched gene sets identified lists that were negatively correlated both with the DEX phenotype and day 15 of micromass cultures. Only transcriptional repressors and molecules involved in the extracellular signal-regulated kinase (ERK) pathway were identified. This pattern is consistent with DEX\'s anti-proliferative functions, as another study showed that DEX decreases ERK phosphorylation and thus cell cycle progression in a pre-osteoblast cell line \[[@B77]\]. Altogether this analysis shows that DEX regulation of growth plate chondrocyte differentiation is multifaceted. The patterns identified here are in agreement with a dual role of DEX in maintenance of the cartilage phenotype and delay in the cartilage-to-bone transition, as we suggested above.

We also wanted to determine whether DEX target genes identified in the current study were similar to DEX-responsive genes identified in alternate studies, in different cell types \[[@B88]\]. Out of a total of twelve microarray studies evaluating the transcriptional effects of DEX treatment on a specific tissue or cell type, only ten genes were common to at least three of the chosen DEX studies. Specifically, bone morphogenetic protein 2 (*Bmp2*), delta sleep inducing factor 1 (*Dsip1*), beta-2 microglobulin (*B2m*), neuroepithelial cell transforming gene 1 (*Net1*), TNFAIP3 interacting protein 1 (*Tnip1*), bone marrow stromal cell antigen 2 (*Bst2*), B-cell leukemia/lymphoma 6 (*Bcl6*), nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha (*Nfkbia*), FK506 binding protein 5 (*Fkbp5*) and B-cell translocation gene 1, anti-proliferative (*Btg1*) were identified. It therefore appears that while DEX affects similar functional categories across various species, tissue types and experimental conditions, the individual genes that respond to DEX treatment are variable. These results also reinforce the paradigm that GC regulation is inextricably linked to its physiological context \[[@B88]-[@B99]\].

Analyses of GC response elements in dexamethasone target genes in chondrocytes
------------------------------------------------------------------------------

Classical genomic GC action is thought to be mediated by a cytoplasmic GR that modifies transcription upon binding its cognate ligand and translocating to the nucleus. In the nucleus, the GR binds a GRE sequence. GR can both activate and repress transcription, depending on the GRE variant present in the regulatory regions of GC target genes \[[@B100]\]. Binding to composite GREs involves homodimerization of the GR to bind a non-palindromic consensus sequence comprised of two GR binding sites and is generally associated with transcriptional activation. In some instances, however, GR can function to block access or activity of transcription factors within promoter regions of certain genes, thus impeding transcription \[[@B101]\]. GR are also able to bind a modified GRE consisting of composite GRE half-sites, termed negative GREs, since they have documented roles in transcriptional repression. Variations on the genomic functions of GC include transcriptional regulation at the level of protein-protein interactions between the GR and other transcription factors, co-activators or co-repressors. In addition to the GRE-dependent roles, the GR is capable of interacting with other co-activators and repressors to influence transcription indirectly \[[@B102],[@B103]\].

The 100 most highly expressed probe sets with greatest enrichment in the DEX or vehicle-treated chondrocytes are shown in Figure [5](#F5){ref-type="fig"}. Probe sets identified in this analysis included both known cartilage markers and established DEX target genes such as *Vegf, Ibsp*, *Bglap2*and *Fkbp5*\[[@B49],[@B63]-[@B66],[@B104],[@B105]\]. We examined the proximal promoter regions of three separate gene lists, the top 100 DEX-responsive transcripts generated by GSEA analysis (Figure [5](#F5){ref-type="fig"}), the 22 091 probe sets deemed expressed in primary chondrocyte cultures and the 1158 transcripts deemed differentially expressed between DEX and vehicle treated cultures by one-Way ANOVA. Specifically, we searched the 9990 base pairs upstream regulatory regions in this list for the composite GRE consensus sequence. We identified putative GRE sequences in many genes, including *Fkbp5*, pyruvate dehydrogenasekinase (*Pdk4*), RANKL (*Tnfsf11*), Interleukin 6 (*Il6*) and prostaglandin I2 synthase (*Ptgis*) (bold in Figure [5](#F5){ref-type="fig"}). However, the majority of DEX-regulated probe sets such as prostaglandin-endoperoxide synthase 2 (*Ptgs2*), phosphodiesterase 4A (*Pde4*), *Vegf*, Period homolog 1 (*Per1*) and Krüppel like factor 15 (*Klf15*) do not appear to contain a GRE in the first 10 kilobases and may by regulated by DEX via a GRE-independent mechanism, through a GRE that deviates from the consensus GRE sequence or through GREs at other locations in the gene.

![**Heat map of top 100 probe sets determined by GSEA analysis**. GSEA-derived heat maps of the top 100 differentially expressed probe sets enriched with DEX or the vehicle control are shown (B). Expression profiles for all experimental replicates are shown for each time point. Genes containing a putative GRE are shown in bold, and examples of genes that do not contain GREs but have been documented as targets of DEX regulation are depicted by bold gray lettering. Signal intensities are illustrated by varying shades of red (up-regulation) and blue (down-regulation).](1471-2164-8-205-5){#F5}

Examination of all lists generated similar results in that approximately 16--20% of all probes contained the consensus GRE. Consequently, we cannot exclude the presence of less conventional GRE loci in the transcripts, or the presence of GREs that deviate from the consensus sequence or are located outside the queried sequence. Since many of the genes affected at the 6 hr time point encode transcription factors, it is likely that a large proportion of the genes that only change after 24 hrs are regulated indirectly by DEX, through altered expression of these transcription factors and other regulatory proteins (e.g. phosphatases and cytokines, as discussed above).

Functional analysis is required to unequivocally evaluate the contribution of GRE-dependent mechanisms to GC regulation in chondrocytes. In addition to the genomic functions of GC, non-genomic modes of GC regulation have been documented. Non-genomic mechanisms are thought to occur through specific and non-specific mechanisms. Specific non-genomic GC regulation occurs through the classical GR and its cytoplasmic heteroprotein complex or non-classical GRs such as membrane GR \[[@B106]-[@B109]\]. Conversely, non-specific non-genomic mechanisms rely on the physiochemical properties of GC and the phospholipid bilayer (Buttgereit and Scheffold, 2002). Further, studies in which candidate molecules are selected and characterized in depth are imperative to discern the specific regulatory mechanisms occurring in chondrocytes.

Conclusion
==========

This study elucidates the downstream transcriptional impact of pharmacological GC exposure on developing chondrocytes. We have identified a small subset of transcripts containing putative GREs in cartilage, but it appears that GRE-independent or indirect mechanisms of GC regulation also contribute to GC regulation in primary chondrocyte monolayer cultures. In addition, traditional microarray analysis methods and gene class testing point to a dual role for pharmacological GC doses in chondrocytes. DEX acts in a gene class-specific manner in cartilage in which it promotes the expression of ECM and metabolic transcripts necessary for maintaining the chondrocyte phenotype while simultaneously downregulating cytokines and growth factors which stimulate the cartilage to bone transition. Understanding the implications of gene expression changes and integrating them into the network of molecules controlling cartilage development continues to be challenging, but robust analytical methods will prove to be useful in constructing the networks of gene interactions and understanding the complex nature of GC signaling in the skeleton. The ultimate objective of this study will be to translate these findings into more efficacious therapeutic GCs.

Methods
=======

Animals and Materials
---------------------

Timed-pregnant CD1 mice were purchased from Charles River Laboratories at embryonic day E15.5 mice (E15.5). Dexamethasone was obtained from Calbiochem and reconstituted in Dimethyl sulfoxide (DMSO, vehicle) according to the manufacturer\'s instructions. Cell culture materials and general chemicals were obtained from Invitrogen, Sigma or VWR unless otherwise stated.

### Primary cell culture and dexamethasone-treatment

Tibiae, femurs and humeri were isolated from E15.5 mouse embryos and placed in α-MEM media (Invitrogen) containing 0.2% Bovine Serum Albumin (BSA), 1 mM β-glycerophosphate, 0.05 mg/ml ascorbic acid and penicillin/streptomycin and incubated at 37°C in a humidified 5% CO~2~incubator overnight. The following morning media was removed and the bones placed in 4 ml of 0.25% trypsin-EDTA (Invitrogen) for 15 min at 37°C. Trypsin was subsequently replaced with 1 mg/ml collagenase P (Roche) in DMEM/10% fetal bovine serum (Invitrogen), and cells were incubated at 37°C with rotation at 100 rpm for 90 min. Following digestion, the cell suspension was centrifuged for 5 min at 1000 rpm, and the collagenase containing supernatant was decanted. Chondrocytes were resuspended in media containing 2:3 DMEM:F12, 10% fetal bovine serum, 0.5 mM L-glutamine, and penicillin/streptomycin (25 units/ml). Cells were seeded in 6-well NUNC plates at a density of 2.5 × 10^4^cells per ml and incubated overnight. Primary monolayer chondrocytes were treated with 10^-7^M dexamethasone (DEX) or the DMSO control (vehicle) diluted in fresh media supplemented with 0.25 mM ascorbic acid (Sigma) and 1 mM β-glycerophosphate (Sigma) and incubated for up to 24 hrs. Micromass cultures were completed as previously described \[[@B50]\].

### Cell counting studies

Chondrocytes were isolated and seeded in 24-well NUNC plates (Nunc Inc.) at a density of 16 000 cells/cm^2^. Cells were cultured, treated and enzymatically digested as described with some modifications. Collagenase digestion occurred for 5 minutes followed by mechanical digestion to liberate cells from the ECM. Cells were counted with a hemocytometer in triplicate with a minimum of 3 individual wells per treatment and three independent cell isolations.

### RNA isolations and quantitative real-time PCR

All RNA protocols were completed as previously outlined \[[@B50]\]. Total RNA was isolated at 6 hrs and 24 hrs after treatment using the RNeasy mini extraction kit (Qiagen) according to the manufacturer\'s instructions. RNA quantity and integrity was assessed using the Bioanalyzer 2000 system (Agilent). Quantitative real-time polymerase chain reaction (qRT-PCR) amplification was completed using the ABI Prism 7900 Sequence Detection System (Applied Biosystems). Triplicate reactions were executed for each sample of each of three independent trials. The TaqMan one-step master mix kit (Applied Biosystems) with gene-specific target primers and probes were used for amplification. The collagen X (*Col10a1*) probe and primer set (forward primer 5\'-ACGCCTACGATGTACACGTATGA-3\', reverse primer 5\'-ACTCCCTGAAGCCTGATCCA-3\', 6-FAM-5\'-AGTACAGCAAAGGCTAC-MGBNFQ) was designed with PrimerDesigner 2.0 software (Applied Biosystems) \[[@B79]\]. TaqMan GAPDH control reagents for house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*, forward primer 5\'-GAAGGTGAAGGTCGGAGTC; reverse primer 5\'-GAAGATGGTGATGGGATTTC; probe JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA) was used as an internal amplification control. Probes for Indian hedgehog (*Ihh*), Tissue inhibitor of matrix metalloproteinase 4 (*Timp4*), Cyclin-dependent kinase inhibitor 1C (*Cdkn1c*, p57), Integrin beta like 1 protein (*Itgbl1*), GC receptor (*Nr3c1*), Integrin beta 1 (*Itgb1*) and Kruppel-like factor 15 (*Klf15*) were assayed using the TaqMan^®^gene expression assays in accordance with the manufacturers directions. Amplified transcripts were quantified using the standard curve method, and the relative transcript abundance was determined by calculating the quotient of the gene of interest and equivalent *Gapdh*values.

Microarray analysis
-------------------

Total RNA was extracted from control and DEX-treated cultures at 6 hr and 24 hr following treatment, in three independent experiments. RNA integrity and quantity was assessed using the Agilent 2000 Bioanalyzer system, and RNA samples were subsequently hybridized to the MOE 430 2.0 mouse chip from Affymetrix^©^containing 45 101 probe sets as described \[[@B50]\]. Bioanalysis, microarray hybridization, scanning and preliminary MAS 5.0 normalizations were completed at the London Regional Genomics Facility. Data were deposited in the GEO database (NCBI; accession number GSE7683).

Data normalization
------------------

Microarray data were pre-processed using the GC-RMA algorithm in Genespring GX\*. Expression values were further filtered by retaining only those probe sets with expression values of at least 50 in at least 25% of all conditions, thus generating a list of 22 091 probe sets. To assess differential gene expression between treatments at both the 6 and 24 hr time points, a Welch ANOVA test with a p-value cut-off of 0.01 and a 5% false discovery rate (FDR) reduced the data to 1158 probe sets. Subsequent 1.5-, 5- and 10-fold change filters produced lists of 162, 21 and 7 probe sets for the 6 hr time point and 399, 53 and 19 probe sets for the 24 hr time point, respectively.

The same data set was normalized in parallel using Robust Multichip Analysis using RMAEXPRESS software v.0.4.1 developed by B. Bolstad, University of California, Berkeley \[[@B110]\]. Background adjustment and quantile normalization parameters were selected for data processing. Logarithmically transformed expression values were used to implement Gene Set Enrichment Analysis (GSEA).

### Gene set enrichment analysis (GSEA)

The GSEA algorithm was implemented with GSEA v2.0 software \[[@B51],[@B52]\]. Ranked expression lists were derived from RMAEXPRESS and GeneSpring GX^®^7.3.1. Briefly, the GSEA algorithm ranks all array genes according to their expression under each experimental condition. The resulting ranked metric score (RMS) is therefore a function of the correlation between a gene\'s signal intensity, the experimental conditions in question and all other genes in the data set. An enrichment score (ES) is then calculated for an a priori gene list or gene set that is associated with a particular molecular classification. In our analysis, gene sets were created from different functional groupings, molecular classifications, tissues, and other microarray screens. A Ranked enrichment score (RES) which determines the extent to which a given gene from a gene set is represented at the extremes of the ranked gene list is then calculated. Specifically, this value is obtained by walking along the ranked list using a cumulative sum statistic which increases when a member of a particular gene set is found in the ranked gene list and is coordinately penalized when it does not appear in the gene set. A null distribution of ES is subsequently generated by permutation filtering to evaluate the statistical significance of the observed RES values. Permutation filtering randomly assigns the experimental conditions or class labels (i.e., DEX versus vehicle) to the different microarray samples. After this procedure has been repeated for each gene set, the ES are normalized (NES) to account for differences in gene set size. The false discovery rate (FDR) is then calculated relative to the NES values to determine the false-positive rate. Significant FDR and p-values were less than 25% and 0.001, respectively in accordance with GSEA recommendations.

### Gene set creation

Gene sets were generated using the probe set search tool and the molecular function class of Gene Ontology annotations in GeneSpring GX. Additional gene sets were created using lists from pairwise comparisons between day 3 and 15 of a previously generated micromass data set (James et al., 2005), and publications that identified DEX target genes in other cartilage array screens, other tissue types and experimental systems. A total of 2119 probe sets showing a minimum 1.5-fold change in gene expression were used in the analysis. Probe set redundancy was eliminated in all gene sets using the CollapseDataset function in the GSEA program. All probe set identifiers were assimilated to the Human Genome Organization (HUGO) annotations. Probe sets lacking corresponding HUGO annotations were excluded from the analysis. Default parameters were used to execute the analysis and median values taken to represent the range of duplicated probe sets for a given gene. A total of 77 user-defined gene sets were generated from GeneSpring derived Gene Ontology annotations for various molecular classifications and probe sets of differentially expressed genes between days 3 and 15 of micromass culture (James et al., 2005).

### Glucocorticoid response element (GRE) analysis

Putative GRE were identified with the GenespringGX mouse genome9999 application which allows sequences up to 9999 bp upstream of the transcriptional start sites of all annotated MOE4302.0 transcripts to be interrogated for transcription factor binding sites. The GR consensus sequence GGTACAnnntgttCT \[[@B111]\] was queried from 10 bp to 10 000 bp upstream of the transcriptional start sites of available probe sets. The GRE consensus sequence was screened against 10 748 probe sets derived from the list of 22 091 reliably expressed probe sets exhibiting homology to upstream regulatory regions annotated in the program. Only exact matches were retained for subsequent analyses out a total of 1,073,741,824 tests.
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